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Background: Deregulation of the EGFR signaling pathway is one of the most frequently observed genetic
abnormalities that drives cancer development. Although mutations in the downstream components of the EGFR
signaling pathway, including KRAS, BRAF and PIK3CA, have been reported in numerous cancers, extensive mutation
and copy number analysis of these genes in clinical samples has not been performed for head and neck squamous
cell carcinoma (HNSCC).
Methods: We examined the mutations and copy number alterations of KRAS, BRAF and PIK3CA in 115 clinical
specimens of HNSCC obtained from surgically treated patients.
We used DNA sequencing to detect mutations and the copy number changes were evaluated by qPCR and array
comparative genomic hybridization (CGH) analysis.
Results: We examined the mutations and copy number alterations of KRAS, BRAF and PIK3CA in 115 clinical
specimens of HNSCC obtained from surgically treated patients. We identified 3 mutations (2.6%) in K-RAS and 3
mutations (2.6%) in PIK3CA. Copy number amplification was found in 37 cases (32.2%) for PIK3CA, 10 cases (8.7%) for
K-RAS and 2 cases (1.7%) for BRAF. Kaplan-Meier survival analysis revealed that copy-number amplification of PIK3CA
was markedly associated with cancer relapse in patients without lymph node metastasis. (Log-rank test, p = 0.026)
Conclusions: Copy number amplification of the PIK3CA gene is associated with poor prognosis in HNSCC patients
without lymph node metastasis. The PIK3CA copy number status will serve as a marker of poor prognosis in patients
with HNSCC.
Keywords: PIK3CA, KRAS, BRAF, Copy number analysis, Prognostic FactorBackground
Progress in genomics has led to the identification of
oncogenes, and genetic mutations associated with car-
cinogenesis have been reported for many carcinomas.
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reproduction in any medium, provided the oranother major mechanism of oncogene activation [1]. In
addition to progress in the understanding of signaling
pathways, there have been pharmaceutical advances with
regard to the development of drugs that target proteins
in membrane receptors and the downstream signals
associated with carcinogenesis. Various trials have been
performed to assess individualized drugs for the treat-
ment of cancer that target the patients’ individual gen-
etic makeup, and numerous agents targeting various
cancer-related proteins have recently been developed.
Recent studies have shown that the over expression of
epidermal growth factor receptor (EGFR) is associatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Primer sequences and annealing temperatures
for direct sequencing
Gene Exon Primer sequence Tm,




KRAS 1 F,5’-CATTACGATACACGTCTGCAGTCAACTGG-3’ 52
R,5’-GTGAACATCATGGACCCTGACATACTCC-3’
BRAF 15 F,5’-TCATAATGCTTGCTCTGATAGGA-3’ 52
R,5-GGCCAAAATTTAATCAGTGGA-3’
F, forward primer R, reverse primer Tm, annealing temparature.
We used DNA sequencing to detect mutations in the clinical HNSCC
specimens. KRAS (exons 1 and 2), BRAF (exon 15) and PIK3CA (exons 9 and 20)
were analyzed for mutations.
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squamous cell carcinoma (HNSCC) [2]. In a previous
study, we analyzed the mutations and phosphorylation
status of EGFR in patients with HNSCC and showed
that the hyperphosphorylation of EGFR was a prognostic
factor for poor survival [3]. Accordingly, the EGFR sig-
naling pathway has attracted attention in the field of
HNSCC as a promising target for molecularly targeted
treatment. Indeed, cetuximab, a chimeric monoclonal
antibody directed against human EGFR, has been
reported to be effective in the treatment of advanced
HNSCC [4].
Upon binding with a ligand, EGFR activates multiple
intracellular signaling pathways, including the RAS/
RAF/mitogen-activated protein kinase (MAPK) pathway
and the phosphoinositide 3-kinase (PI3K)/AKT/mam-
malian target of rapamycin (mTOR) pathway, which
transmit extracellular signals to the nucleus to control
cell growth and proliferation. In many types of malig-
nancies, such as lung cancer and colorectal cancer,
mutations in the genes encoding EGFR or downstream
components of the signaling pathways are highly preva-
lent [5,6]. Interestingly, these mutations are often asso-
ciated with the effectiveness of molecularly targeted
drugs. For instance, mutations in KRAS are effective
predictors of colorectal cancer patients’ responses to
cetuximab [7], and mutations in PIK3CA are correlated
with resistance to cetuximab treatment in colon cancer
cell lines [8]. Therefore, in the era of personalized can-
cer therapy, it will be important to know whether these
mutations are present in tumors to plan effective
therapeutic strategies for patients. So we determined a
type of the mutation to investigate in reference to
some theses about HNSCC in KRAS, BRAF, and
PIK3CA [9,10].
In addition to gene mutations, copy number altera-
tions of EGFR, KRAS, PIK3CA and other signaling med-
iators are also critical factors that drive cancer
development and determine prognoses and the sensitiv-
ity to anticancer drugs. In NSCLC, EGFR gene copy
amplification, as determined by FISH, was shown to
likely be associated with poor prognosis and with
improved survival upon treatment with EGFR tyrosine
kinase inhibitors [11]. As for HNSCC, several reports
have shown that EGFR copy number alterations are
associated with a poor prognosis [12]; it is also reported
that PIK3CA copy number amplification is associated
with lymph node metastasis [13].
Little is known about the frequency of mutations and
copy number alterations of genes other than EGFR that
encode components of the RAS and PI3K pathways in
HNSCC. Herein, we present a sequence and copy num-
ber analysis of the RAS, RAF and PI3K genes in a collec-
tion of 115 clinical samples.Methods
Patients
This prospective cohort study was approved by the Eth-
ics Committee for Biomedical Research of the Jikei Insti-
tutional Review Board, Jikei University School of
Medicine, Tokyo, Japan. All of the patients provided
written informed consent. Between September 2006 and
August 2009, 115 tumors were obtained from 115
HNSCC patients who underwent surgery at the Depart-
ment of Head and Neck Surgery, Jikei University Hos-
pital. And they were consecutively submitted by surgical
management. Clinical information was obtained from
the clinical and surgical charts. Based on the postopera-
tive staging, the tumor-node-metastasis (TNM) classifi-
cation and stage were determined according to the 6th
UICC TNM classification and stage groupings [14].
Tumor samples
In each case, the tumor samples from the primary site
and surrounding normal tissue, but not the metastatic
sites, were stored at −80°C after excision. The cancer
tissue was divided into two specimens: one for patho-
logical confirmation in which the sample was composed
of >70% cancer cells and the other for DNA and protein
extraction.
Mutation analysis
We used DNA sequencing to detect mutations in the
clinical HNSCC specimens. Polymerase chain reaction
(PCR) amplification of genomic DNA was performed,
and the following genes were analyzed for mutations:
KRAS (exons 1 and 2); BRAF (exon 15); and PIK3CA
(exons 9 and 20). These regions included those with the
most common mutations previously observed in human
cancer. Table 1 shows the primers and annealing tem-
peratures used in the PCR analysis. The sequencing of
the PCR products was performed using the ABI PRISM
Large Dye Terminator Cycle Sequencing Ready Reaction
Table 3 Patients’ characteristics
Variable Total (n = 115)
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plied Biosystems, Foster City, CA).
Analysis of copy number by quantitative PCR
The copy number changes in KRAS, BRAF and PIK3CA
were evaluated by qPCR using the qPCRTM MasterMix
for SYBR Green, as previously reported [15]. Table 2
shows the primer and annealing temperatures used in
the qPCR; the qPCR reactions for each sample and each
gene were performed in triplicate. Each copy number
calculation was performed using the comparative Ct
method [16]. DNA from the normal tissue from each
sample was used as the control [17]; each gene copy
number in the normal tissue was set as 2, and a copy
number more than 4 was considered to be a gain, as in a
previous study [18].
Analysis of the copy number by array CGH
For the samples with copy number amplification identi-
fied by qPCR, we performed an array comparative gen-
omic hybridization (CGH) analysis using microarray
slides that contained 180,000 probes (Agilent Technolo-
gies, Santa Clara, CA, USA) [19]. We defined log2 ratio
+0.5 < as gain and −0.5 > as loss and all other amounts
as normal.
Statistical analysis
The Student t-test, chi-squared test and Fisher test were
used to evaluate differences in the patients’ characteris-
tics stratified by the copy number alternation. Disease-
free survival curve’s end point is defined by recurrence
(local relapse, new lymph node metastasis or distant me-
tastasis) during follow. All patients conducted observa-
tion within two month after surgery and patients were
periodically (every 0.5–2 months) examined on an out-
patient basis to make sure they had not relapsed. Exami-
nations consisted of standard tests, including endoscopy
and computed tomography of the chest and neck. It was
defined recurrence when a carcinoma was detected again
in a primary tumor and cervical lymph node or distantTable 2 Primer sequences and annealing temperatures
for copy number analysis by qPCR
Gene Primer sequence Tm,
PIK3CA F,5’- GCAAAGGTTGGTCGGTGAA -3’ 60
R,5’- GTGATCTTTGATGTTACTCTGATGCA -3’
KRAS F,5’- CACCCTAGACAAGCAGCCAATA -3’ 60
R,5’- AAGCCCTGCCGCAAAAA -3’
BRAF F,5’- CAAGTCACCACAAAAACCTATCGT -3’ 60
R,5- AACTGACTCACCACTGTCCTCTGTT -3’
The copy number changes in KRAS, BRAF and PIK3CA were evaluated by
qPCR. DNA from the normal tissue from each sample was used as the control;
each gene copy number in the normal tissue was set as 2, and a copy number
more than 4 was considered to be a gain.metastases were observed on computed tomography.
Over-all survival and disease-free survival curves were
generated using the Kaplan-Meier method and com-
pared using log-rank tests. Cox proportional hazard
models were fitted for multivariate analysis adjusting for
age, gender, smoking status, mutation status of KRAS
and PIK3CA, and amplification status. Adjusted hazard
ratios (HR) and 95% confidence intervals (CI) were com-
puted. All of the statistical analyses were performed
using STATA 9.1 (STATA Corp., College Station, TX). A
p value < 0.05 was considered statistically significant.
Results
Patients’ characteristics
The patients ranged in age from 32 to 88 years, and
there were more men than women in the cohort. Most
of the patients had oropharyngeal or oral cavity cancer,
and 47% had stage IV disease. The patient characteristics
are listed in (Table 3).
Mutation analysis of KRAS, BRAF and PIK3CA
We conducted a sequencing analysis to examine the fre-
quency of mutations in the KRAS, BRAF and PIK3CA
genes, and we investigated the correlations between the
presence of mutations and the clinical data. Specifically,
we sequenced KRAS exon 1and exon2, BRAF exon 15
and PIK3CA exon 9 and exon 20 and identified muta-
tions in 6 of the 115 patients (5.2%). Three mutations
were observed in exon 1 of KRAS, and all were the same
substitution (G12A). No mutation was found in exon 2.
The primary tumors included two oral cavity carcinomas






T stage: T1/T2/T3/T4 16/45/27/27
(13.9%/39.1%/23.5%/23.5%)




115 patients were obtained in this study. The patient characteristics are listed.
Table 5 Copy number alteration of K-RAS, PI3CA, BRAF
Not Amplified Amplification Deletion
K-RAS (12p12.1) 103(89.6%) 10(8.7%) 2(1.7%)
PIK3CA(3q26.3) 77(67.0%) 37(32.1%) 1(0.9%)
BRAF (7q34) 106(92.2%) 2(1.7%) 7(6.1%)
We identified copy number changes in PIK3CA, K-RAS and BRAF. PIK3CA copy
number amplification was found in 37 cases (32.2%).
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score (more than 30 pack-years), and the others had low
scores [20]. Three mutations in PIK3CA were found:
two in exon 9 and one in exon 20, and all of the muta-
tions were substitutions (E545K and H1047R). The pri-
mary tumors were two oral cavity carcinomas and one
laryngeal carcinoma, and all three patients were non-
smokers. No BRAF mutations were detected (Table 4).
Significant association was absent about the association
between these mutations and clinical data (localization,
sex, age,stage etc.).
Copy number analysis of KRAS, BRAF and PIK3CA
We identified copy number changes in PIK3CA, K-RAS
and BRAF. PIK3CA copy number amplification was
found in 37 cases (32.2%), whereas only 10 cases (8.7%)
were found for K-RAS and 2 cases (1.7%) for BRAF
(Table 5). In PIK3CA amplified cases, one case had
PIK3CA mutation, 2 cases had KRAS mutation and no
case had both mutations. The patients’ characteristics
stratified by the PIK3CA copy number alteration are
shown in (Table 6); there was no significant association.
As with PIK3CA, no difference was observed for the
KRAS and BRAF copy number alternation (data not
shown).
Kaplan-Meier curves of over-all survival and disease-free
survival by Copy number status
Tumor recurrence and death occurred in 49 patients
(42.6%) and 22 patients (19.1%), respectively during the
median follow-up period of 723 days. Over-all survival
and disease-free survival curves were generated using
the Kaplan-Meier method, and log-rank tests were used
to determine if survival was associated with the copy
number status of PIK3CA. There was no significant as-
sociation between the copy number status (with or with-
out amplification) in PIK3CA and the over-all survival
and disease-free survival (Log-rank test, p = 0.45 and
p = 0.26) (Figure 1). We conducted same examination in
KRAS copy number status, and the significant difference
was not found in the copy number status and prognosis.
However, after excluding the patients with lymph node
metastasis, the disease-free survival curves drawn usingTable 4 HNSCC gene mutations
No Nucleotide change Amino acid Change
12 Substitution of G for C at nucleotide 35 G12A Or
21 Substitution of G for C at nucleotide 35 G12A Orop
30 Substitution of G for C at nucleotide 35 G12A Or
10 Substitution of A for G at nucleotide 3140 H1047R La
51 Substitution of G for A at nucleotide 1633 E545K Or
53 Substitution of G for A at nucleotide 1633 E545K Or
We sequenced KRAS exon 1, BRAF exon 15 and PIK3CA exon 9 and exon 20 and idthe Kaplan-Meier method about 59 patients without
lymph node metastasis (N stage = N0 patients) indicated
that the patients with PIK3CA copy number amplifica-
tion (n = 16) showed earlier recurrence than those
without PIK3CA copy number amplification (n = 43)
(log-rank test, p =0.026) (Figure 2). Of those with
PIK3CA copy number amplification, 31% were disease-
free at 2.0 years, whereas 90% of the patients without
PIK3CA copy number amplification survived without re-
currence during the study period. Actually 19 patients
had a recurrence in PIK3CA amplified patients and
30 patients had a recurrence in not amplified patients.
Copy number amplification of the PIK3CA is associated
with poor prognosis in HNSCC patients without lymph
node metastasis.
Cox proportional hazard models with multivariate
adjustment
Cox proportional hazard models with disease-free sur-
vival were computed to determine the significance of
PIK3CA amplification with adjustment for age, gender,
smoking status and mutation status (Table 7). Without
multivariate analysis, PIK3CA amplification showed a
significant crude HR. With multivariate analysis, patients
with PIK3CA amplification showed poor prognostic
markers: adjusted HR, 3.13; 95% CI, 1.16 to 8.40;
P =0.024. In contrast, the factor (age, gender, smoking
status and mutation status) showed no significant associ-
ation with disease-free survival.
Discussion
The overall mutation frequency of KRAS, BRAF and
PIK3CA in our HNSCC samples was lower than
reported for other cancers. We identified mutations in
2.6% of our samples for the KRAS gene, 2.6% forPrimary tumor Exon Smoking (pack/year) Age/Sex
al Cavity (T3N0M0) KRAS Exon1 45 51/M
haryngeal (T2N0M0) KRAS Exon1 10 47 /M
al Cavity (T3N1M0) KRAS Exon1 0 54/M
ryngeal (T3N0M0) PIK3CA Exon20 0 61/M
al Cavity (T1N1M0) PIK3CA Exon9 0 79/M
al Cavity (T3N0M0) PIK3CA Exon9 0 82/M
entified mutations in six of the 115 patients (5.2%).
Table 6 Patients’ characteristics stratified by Copy number alternation of PIC3CA
Variable Copy number of PIK3CA (Not Amplified n = 78) Copy number of PIK3CA (Amplification n = 37) P value
Age: mean ± SD 64.8 ± 11.6 65.6 ± 9.9 0.60*
Sex: Male/Female 63 / 15 30 / 7 0.96†
Number of metastatic






Oral cavity 22(28.2%) 9(24.3%)
Nasal cavity 10(12.8%) 1(2.7%)
Tumor grade: 28/35/15 18/12/7 0.37†
well/ moderate/poor (35.9%/44.9%/19.2%) (48.6%/32.4%/18.9%)
TNM classification
T stage: T1/T2/T3/T4 12/30/17/19 4/15/10/8 0.85†
(15.3%/38.5%/21.8%/24.4%) (10.8%/40.5%/ 27.0%/21.6%)
N stage: N0/N1/N2 43/12/23 16/5/16 0.34†
(55.1%/15.4%/29.5%) (43.2%/13.5%/43.2%)
Stage : I/ II/III/IV 11/16/17/34 1/7/9/20 0.28†
(14.1%/20.5%/21.8%/43.6%) (2.7%/18.9%/ 24.3%/54.1%)
Pack-year(tobacco) mean ± SD 19.6 ± 24.3 22.3 ± 24.6 0.64*
* Student t test † Chi-square test ‡ Fisher test.
The patients’ characteristics stratified by the PIK3CA copy number alteration. There was no significant association.
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observed in approximately 45-60% of pancreatic cancers
[21,22], 30-50% of colorectal cancers [23,24] and 30% of
non-small-cell lung carcinomas [25]. BRAF mutations are
observed in approximately 60-70% of malignant melanomas
[26,27], 40% of thyroid carcinomas [28] and 5-10% of colo-
rectal cancers [29]. PIK3CA mutations are observed in 32%
of colorectal cancers [30], 31% of endometrial cancers [31]
and 14% of breast cancers [32]. The small sample size may
have caused less frequency of these mutations in the study.
The KRAS mutations identified in three of our tumor
samples (2.6%) were identical G12A substitutions, which
is a well-characterized activating mutation. The low
KRAS mutation frequency in the present study is in
agreement with previous small-scale studies of HNSCC
that reported a mutation frequency of 2.4% (1/42 sam-
ples) in oral squamous cell carcinoma [10], 4.5% (1/22
samples) in oropharyngeal cancer [33] and 0% (0/16
samples) in HNSCC [9]. We also found that the fre-
quency of copy number amplification was not high
(8.7%), suggesting that approximately 90% of the patients
have normal KRAS proteins and that the hyper activa-
tion of KRAS, per se, is not a common feature of
HNSCC. A recent study showed that KRAS mutations
result in resistance to cetuximab in colorectal cancer,
limiting the utility of this drug [34]. In lung cancer,although the frequency of KRAS mutations is similar to
that in colorectal cancer, these mutations are not
reported to be a predictive marker. Therefore, the low
KRAS mutation frequency of HNSCC may cause diffi-
culty in predicting the effect of cetuximab and other
EGFR inhibitors.
We analyzed exon 15 of BRAF to search for a V600E
substitution, the most common activating mutation of
BRAF, which is observed at high frequencies in various
cancers [35]. However, we did not detect any V600E
mutations in our samples, and the frequency of copy
number alteration was also low, at 1.7% (2/115). To-
gether with a previous study that reported a BRAF mu-
tation frequency of 2.4% (1/42) in oral squamous cell
carcinoma [10], our results suggest that the BRAF muta-
tion frequency is much lower in HNSCC than in other
cancers.
Mutations in exons 9 and 20 of PIK3CA were found
in three specimens (2.6%), and these mutations are
known to be hotspot mutations that generate a constitu-
tively active kinase in other cancers [36]. The mutation
frequency of PIK3CA in our study was somewhat lower
than that reported in previous small-scale studies. One
study of surgical specimens from 30 Americans with
HNSCC and eight HNSCC cell lines found mutations in
four out of the 38 samples (10.5%) [37]. Another study
Figure 1 115 patients with PIK3CA copy number status. Kaplan-Meier curves for disease-free survival (A) and over-all survival (B). Patients
were with or without PIK3CA copy number amplification. The p-values were estimated using the log-rank test.
Figure 2 Restricting 59 patients without lymph node metastases. Kaplan-Meier curves for disease-free survival. Patients with or without
amplification in PIK3CA, restricting to 59 patients without lymph node metastases. The p-values were estimated using the log-rank test.
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Table 7 Cox proportional hazard models (59 patients without lymph node metastasis)
Variable Crude HR 95% CI P value AHR 95% CI P value
PIK3CA amplification 2.83 1.08-7.36 0.003 3.13 1.16-8.4 0.024
Mutation (PIK3CA K-Ras) 0.73 0.09-5.6 0.77 0.83 0.1-6.78 0.86
Age 0.97 0.93-1.00 0.13 0.95 0.91-1.0 0.075
Gender 1.22 0.52-2.84 0.64 1.06 0.42-2.65 0.89
Smoking status 1.01 0.99-1.03 0.08 1.02 0.99-1.04 0.06
Adjusted for age, gender, smoking status, mutation status.
HR, hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio.
Cox proportional hazard models were computed to determine the significance of PIK3CA amplification with adjustment for age, gender, smoking status and
mutation status.
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lines among 54 cases, including 17 cell lines and 18 sur-
gical specimens from Vietnamese patients and 19 surgi-
cal specimens from Indian patients [38]. The lower
mutation frequency may reflect differences in the genetic
backgrounds or may be due to the small population
sizes. Although the frequency of point mutations in
PIK3CA was low, we found copy number amplification
in 37 samples (32.2%), suggesting that the hyper activa-
tion of the PI3K pathway occurs in one-third of HNSCC
patients. PIK3CA mutations are associated with resist-
ance to cetuximab in colorectal cancer in vitro [8]. Fur-
thermore, a phase I study of a recently developed mTOR
inhibitor found that colorectal cancer patients with
PIK3CA mutations had a higher response rate than
those without mutations [39]. Thus, checking the status
of the PIK3CA gene will be important when using
these molecularly targeted drugs in HNSCC patients.
However, the low frequency of mutation in PIK3CA
complicates its utility as a predictive marker for use in
molecularly targeted medicine in clinical settings.
In our analysis, an amplification of the PIK3CA copy
number was found in many of the samples (32.2%). With
regard to lung cancer, such amplification is more
frequent in squamous cell carcinomas (33.1%) than
adenocarcinomas (6.2%) [40]. Interestingly, Fendri et al.
reported that the frequency of amplification was 21.6%
and was associated with lymph node metastasis and with
the overall survival in nasopharyngeal cancer [41]. In
HNSCC, metastatic lymph nodes are very strongly asso-
ciated with disease progression and clinical staging: the
cancer is considered stage III or IV when lymph node
metastases are found. Therefore, we hypothesized that
the copy number amplification of PIK3CA was asso-
ciated with a poor prognosis. The frequency of the copy
number alteration observed in the present study was the
same as in other reports, yet we found no significant dif-
ference in the disease-free survival and overall survival
between patients with PIK3CA amplification and those
without amplification. However, when the patients with
lymph node metastases were excluded from the popula-
tion, a significant correlation was found betweenPIK3CA copy amplification and the time to relapse (log-
rank test, p =0.026). As cancer relapse occurs in the
lymph nodes in most cases, the amplification of the
PIK3CA copy number is likely to promote the process of
lymph node metastasis in early-stage patients. Our evi-
dence further suggests that those patients with early-
stage HNSCC may be divided into two subgroups of
good and poor prognoses, as defined by the copy num-
ber status of PIK3CA.
The limitations of this study include the small number
of patients especially about the prognosis study by the
status of the copy number and may be include the selec-
tion bias in undergoing surgery.Conclusions
We examined the mutations and copy number altera-
tions of KRAS, BRAF and PIK3CA in 115 clinical
specimens of HNSCC. We identified 3 mutations (2.6%)
in K-RAS and 3 mutations (2.6%) in PIK3CA. Copy
number amplification was found in 37 cases (32.1%) for
PIK3CA, 10 cases (8.7%) for K-RAS and 2 cases (1.7%)
for BRAF. Kaplan-Meier survival analysis revealed that
copy-number amplification of PIK3CA was markedly
associated with cancer relapse in patients without lymph
node metastasis. (Log-rank test, p = 0.026) Copy number
amplification of the PIK3CA gene is associated with
poor prognosis in HNSCC patients without lymph node
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